Calabasas, CA – July 9, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, has joined the Russel Microcap® Index following the conclusion of the 2025 Russel indexes annual reconstitution.
The annual Russel US Indexes reconstitution captures the 4,0 largest US stocks, ranking them by total market capitalization. Membership in the Russel Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russel determines membership for its Russel indexes primarily by objective, market-capitalization rankings, and style attributes. Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
“Joining the Russel Microcap® Index is a powerful validation of NeOnc’s momentum and our unwavering commitment to shareholder value and patient impact,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. “This index represents microcap companies with an average market cap of about $640 million, covering stocks between roughly $30 million and $3 billion across fewer than 3% of the patient impact,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. “This index represents microcap companies with an average market cap of about $640 million, covering stocks between roughly $30 million and $3 billion across fewer than 3% of the U.S. equity market. Over the past year, we’ve been intensely focused on advancing our Phase I clinical trials in CNS cancers and strategically expanding into the MENA region through our proposed Quazar partnership in the GC. Our ultimate goal remains the same: to generate meaningful shareholder returns while making a real difference for patients and families battling brain cancer. shareholder returns while making a real difference for patients and families battling brain cancer.”
Russel indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russel’s US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russel indexes are part of FTSE Russel, the global index provider. strategies. Russell’s US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider.
For more information on the Russel Microcap® Index and the Russel indexes reconstitution, go to the “ Russell Reconstitution” section on the FTSE Russel website.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate,” or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
